CPIX
Cumberland Pharmaceuticals Inc.
CPIX has the edge over NVO overall, supported by stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
CPIX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
CPIX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CPIX PE Valuation
CPIX has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CPIX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
CPIX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CPIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.73 | -$0.51 |
| Q1 2026 | -$0.49 | -$0.24 |
| Q4 2025 | -$0.19 | +$0.28 |
| Q3 2025 | -$0.24 | +$0.53 |
| Q2 2025 | -$0.22 | +$0.51 |
| Q1 2025 | -$0.25 | +$0.34 |
| Q4 2024 | -$0.47 | -$0.03 |
| Q3 2024 | -$0.77 | -$0.60 |
CPIX lost $0.73 per share over the past year, a bigger loss than the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CPIX on earnings quality, reporting a profit while its opponent remains loss making.
CPIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.8M | -19% |
| Q1 2026 | $9.1M | -22% |
| Q4 2025 | $13.7M | +31% |
| Q3 2025 | $8.3M | -8.7% |
| Q2 2025 | $10.8M | +10% |
| Q1 2025 | $11.7M | +38% |
| Q4 2024 | $10.4M | +12% |
| Q3 2024 | $9.1M | -9.9% |
CPIX's revenue is shrinking: $9M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -36% | -29 points |
| Q1 2026 | -34% | -45 points |
| Q4 2025 | -10% | +7.6 points |
| Q3 2025 | -24% | -5.1 points |
| Q2 2025 | -6.9% | +3.5 points |
| Q1 2025 | 11% | +33 points |
| Q4 2024 | -18% | +48 points |
| Q3 2024 | -19% | -0.1 points |
CPIX's operating margin was −36% last quarter, down 29 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CPIX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CPIX on profitability, with a higher operating margin.
CPIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $130.5K | -84% |
| Q1 2026 | $387K | -90% |
| Q4 2025 | $3K | -100% |
| Q3 2025 | $163.4K | -64% |
| Q2 2025 | $817.3K | +$1.7M |
| Q1 2025 | $3.9M | +$6M |
| Q4 2024 | $1.9M | +92% |
| Q3 2024 | $460.1K | -61% |
CPIX still generates free cash flow, though less than at its 2023 peak: $683,899 over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CPIX on cash flow, with more consistent year-over-year improvement.
CPIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +21.4K shares |
| 1 year | +0.1% | +21K shares |
| 3 years | +2.9% | +427K shares |
| 5 years | -0.8% | -128K shares |
| Available history | -2.5% | -386K shares |
CPIX has 15M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $61,001 |
| Q4 2025 | — |
| Q3 2025 | $10,439 |
| Q2 2025 | $7,171 |
| Q1 2025 | $245,868 |
| Q4 2024 | $98,383 |
| Q3 2024 | $98,815 |
CPIX has spent almost nothing on buybacks in the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CPIX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CPIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -4.6x | Net Cash |
| Q3 2025 | -7.5x | Net Cash |
| Q2 2025 | -6.4x | Net Cash |
| Q1 2025 | -6.5x | Net Cash |
| Q2 2023 | -11.7x | Net Cash |
| Q4 2019 | -12.4x | Net Cash |
CPIX has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CPIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.4 | Neutral |
| Stochastic | 26.9 | Neutral |
CPIX's weekly RSI is 51 (neutral) and its Stochastic is 27 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CPIX PE vs Healthcare Sector
CPIX has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CPIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.78 | 2.2% below |
| 20 week MA | $6.94 | 4.5% below |
| 50 week MA | $5.33 | 24% above |
| 100 week MA | $4.51 | 47% above |
| 200 week MA | $3.12 | 113% above |
CPIX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CPIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.14 | $3.06 | -40% |
| 2021 | $3.06 | $5.12 | +67% |
| 2022 | $5.12 | $2.11 | -59% |
| 2023 | $2.11 | $1.79 | -15% |
| 2024 | $1.79 | $2.32 | +30% |
| 2025 | $2.32 | $4.12 | +78% |
| 2026 YTD | $4.12 | $6.63 | +61% |
CPIX has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.